Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel 1H-magnetic resonance spectroscopy and 18F-fluorodeoxyglucose positron emission tomography

ObjectivesTo prospectively compare performances of single-voxel proton magnetic resonance spectroscopy (1H-MRS) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in predicting pathologic response to neoadjuvant chemotherapy (NAC) in breast cancer patients.MethodsThirty-five breast cancer patients who received NAC and subsequent surgery were prospectively enrolled. MRS and FDG-PET were performed before and after the 1st NAC cycle. Percentage changes of total choline-containing compounds (tCho) via MRS, and maximum and peak standardized uptake values (SUVmax, SUVpeak) and total lesion glycolysis (TLG) via FDG-PET were measured, and their performances in predicting pathologic complete response (pCR) were compared.ResultsOf the 35 patients, 6 showed pCR and 29 showed non-pCR. Mean % reductions of tCho, SUVmax, SUVpeak, and TLG of the pCR group were larger than those of the non-pCR group (-80.3 ± 13.9 % vs. -32.1 ± 49.4 %, P = 0.025; -54.7 ± 22.1 % vs. -26.3 ± 33.7 %, P = 0.058; -60.7 ± 18.3 % vs. -32.3 ± 23.3 %, P = 0.009; -89.5 ± 8.5 % vs. -52.6 ± 36.2 %, P = 0.020). Diagnostic accuracy (area under ROC curve; Az, 0.911) of the % reduction of tCho was comparable to those of %SUVmax (0.822), SUVpeak (0.862), and TLG (0.879) in distinguishing pCR from non-pCR (all P > 0.05).ConclusionMRS showed comparable performance to FDG-PET in early prediction of pCR in breast cancer patients.Key points• MRS can predict response to NAC in breast cancer post-1stcycle.• Changes in tCho and SUV after NAC reflect tumour cellularity changes.• MRS can be an alternative to FDG-PET in predicting response to NAC.

[1]  Z. Bhujwalla,et al.  Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. , 1999, Cancer research.

[2]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[3]  A. Rieber,et al.  Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy , 2002, European Radiology.

[4]  A. Hutcheon,et al.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.

[5]  D. Yee,et al.  Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. , 2004, Radiology.

[6]  M. Brennan,et al.  Locally advanced and inflammatory breast cancer. , 2005, Australian family physician.

[7]  Ludovic Ferrer,et al.  Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Andreas Makris,et al.  Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2008, Clinical Cancer Research.

[9]  Barbara L. Smith,et al.  Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Tomoko Ogawa,et al.  Monitoring of early response to neoadjuvant chemotherapy in breast cancer with 1H MR spectroscopy: Comparison to sequential 2‐[18F]‐fluorodeoxyglucose positron emission tomography , 2008, Journal of magnetic resonance imaging : JMRI.

[11]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[12]  Winfried Brenner,et al.  Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Kang,et al.  Prognostic Impact of [18F] FDG-PET in Operable Breast Cancer Treated with Neoadjuvant Chemotherapy , 2009, Annals of Surgical Oncology.

[14]  F. Podo,et al.  In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. , 2009, AJR. American journal of roentgenology.

[15]  Hon J. Yu,et al.  Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. , 2009, Radiology.

[16]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Tozaki,et al.  Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method , 2010, Journal of magnetic resonance imaging : JMRI.

[18]  U. Sharma,et al.  Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI) , 2010, NMR in biomedicine.

[19]  J. Bonneterre,et al.  Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. , 2010 .

[20]  Z. Bhujwalla,et al.  Choline metabolism in malignant transformation , 2011, Nature Reviews Cancer.

[21]  Andreas Makris,et al.  Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. , 2011, Radiology.

[22]  A. Tutt,et al.  Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer , 2012, Annals of Surgical Oncology.

[23]  P. Fasching,et al.  Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Yong-il Kim,et al.  Usefulness of Combined Metabolic–Volumetric Indices of 18F-FDG PET/CT for the Early Prediction of Neoadjuvant Chemotherapy Outcomes in Breast Cancer , 2013, Nuclear Medicine and Molecular Imaging.

[25]  T. Nagaoka,et al.  Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. , 2012, Radiology.

[26]  Fiona J Gilbert,et al.  In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature , 2012, Breast Cancer Research.

[27]  L. Esserman,et al.  Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. , 2012, Radiology.

[28]  Carsten Denkert,et al.  Response-guided neoadjuvant chemotherapy for breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Woo Kyung Moon,et al.  Early Prediction of Response to Neoadjuvant Chemotherapy Using Parametric Response , 2015 .

[30]  G. Ceresoli,et al.  Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  S. Rodenhuis,et al.  Combined use of 18F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  Sang Moo Lim,et al.  The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  B. Kang,et al.  Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT , 2015, Journal of Korean medical science.

[34]  R. Wahl,et al.  TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer , 2015, The Journal of Nuclear Medicine.